Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
815 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2014', provides an overview of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 Introduction 8 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Overview 9 Therapeutics Development 10 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics under Development by Companies 12 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics under Investigation by Universities/Institutes 23 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Products Glance 27 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Products under Development by Companies 31 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Products under Investigation by Universities/Institutes 44 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Companies Involved in Therapeutics Development 47 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Assessment 178 Drug Profiles 194 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Recent Pipeline Updates 564 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects 773 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products 779 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Product Development Milestones 781 Appendix 789
List of Tables Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H2 2014 35 Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Comparative Analysis, H2 2014 36 Number of Products under Development by Companies, H2 2014 38 Number of Products under Development by Companies, H2 2014 (Contd..1) 39 Number of Products under Development by Companies, H2 2014 (Contd..2) 40 Number of Products under Development by Companies, H2 2014 (Contd..3) 41 Number of Products under Development by Companies, H2 2014 (Contd..4) 42 Number of Products under Development by Companies, H2 2014 (Contd..5) 43 Number of Products under Development by Companies, H2 2014 (Contd..6) 44 Number of Products under Development by Companies, H2 2014 (Contd..7) 45 Number of Products under Development by Companies, H2 2014 (Contd..8) 46 Number of Products under Development by Companies, H2 2014 (Contd..9) 47 Number of Products under Investigation by Universities/Institutes, H2 2014 49 Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 50 Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..2) 51 Comparative Analysis by Late Stage Development, H2 2014 52 Comparative Analysis by Clinical Stage Development, H2 2014 53 Comparative Analysis by Early Stage Development, H2 2014 54 Comparative Analysis by Unknown Stage Development, H2 2014 55 Products under Development by Companies, H2 2014 56 Products under Investigation by Universities/Institutes, H2 2014 69 Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 70 Products under Investigation by Universities/Institutes, H2 2014 (Contd..2) 71 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by 4SC AG, H2 2014 72 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AB Science, H2 2014 73 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AbbVie Inc., H2 2014 74 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Actinium Pharmaceuticals, Inc., H2 2014 75 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Advenchen Laboratories, LLC, H2 2014 76 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Affichem, H2 2014 77 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Agios Pharmaceuticals, Inc., H2 2014 78 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AIMM Therapeutics B.V., H2 2014 79 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Akinion Pharmaceuticals AB, H2 2014 80 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ambit Biosciences Corporation, H2 2014 81 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Amgen Inc., H2 2014 82 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Antigen Express, Inc., H2 2014 83 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by APIM Therapeutics AS, H2 2014 84 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aprea AB, H2 2014 85 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aptose Biosciences Inc., H2 2014 86 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ariad Pharmaceuticals, Inc., H2 2014 87 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arno Therapeutics, Inc., H2 2014 88 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ascenta Therapeutics, Inc., H2 2014 89 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Astellas Pharma Inc., H2 2014 90 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Astex Pharmaceuticals, Inc., H2 2014 91 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BerGenBio AS, H2 2014 92 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bio-Path Holdings, Inc., H2 2014 93 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BioLineRx, Ltd., H2 2014 94 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BioMAS Ltd., H2 2014 95 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Boehringer Ingelheim GmbH, H2 2014 96 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bristol-Myers Squibb Company, H2 2014 97 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Calithera Biosciences, Inc., H2 2014 98 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cancer Therapeutics CRC Pty Ltd, H2 2014 99 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cantargia AB, H2 2014 100 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cantex Pharmaceuticals, Inc., H2 2014 101 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by CASI Pharmaceuticals Inc., H2 2014 102 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Celator Pharmaceuticals, Inc., H2 2014 103 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Celgene Corporation, H2 2014 104 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cellceutix Corporation, H2 2014 105 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Celldex Therapeutics, Inc., H2 2014 106 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cellectis S.A., H2 2014 107 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cellerant Therapeutics, Inc., H2 2014 108 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Chroma Therapeutics Ltd., H2 2014 109 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Colby Pharmaceutical Company, H2 2014 110 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Constellation Pharmaceuticals, Inc., H2 2014 111 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Coronado Biosciences, Inc., H2 2014 112 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Critical Outcome Technologies Inc., H2 2014 113 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by CTI BioPharma Corp., H2 2014 114 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by CureTech Ltd., H2 2014 115 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2014 116 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cylene Pharmaceuticals, Inc., H2 2014 117 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by DC Prime B.V., H2 2014 118 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by DiNonA Inc., H2 2014 119 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Egenix, Inc., H2 2014 120 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Eisai Co., Ltd., H2 2014 121 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Eli Lilly and Company, H2 2014 122 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by EntreChem, S.L., H2 2014 123 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by EpiZyme, Inc., H2 2014 124 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Erytech Pharma SA, H2 2014 125 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Esperance Pharmaceuticals, Inc., H2 2014 126 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Eureka Therapeutics, Inc., H2 2014 127 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 128 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Fate Therapeutics, Inc., H2 2014 129 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Formula Pharmaceuticals, Inc., H2 2014 130 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Gamida Cell Ltd., H2 2014 131 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Genentech, Inc., H2 2014 132 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Genosco, H2 2014 133 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Genzyme Corporation, H2 2014 134 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by GlaxoSmithKline plc, H2 2014 135 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by GlycoMimetics, Inc., H2 2014 136 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Hybrigenics S.A., H2 2014 137 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Igenica Biotherapeutics, Inc., H2 2014 138 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Immune System Key Ltd., H2 2014 139 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ImmunGene, Inc., H2 2014 140 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ImmunoGen, Inc., H2 2014 141 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2014 142 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Incyte Corporation, H2 2014 143 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Innate Pharma SA, H2 2014 144 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Interprotein Corporation, H2 2014 145 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Janssen Biotech, Inc., H2 2014 146 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Jasco Pharmaceuticals, LLC., H2 2014 147 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Johnson & Johnson, H2 2014 148 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Kainos Medicine, Inc., H2 2014 149 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by KaloBios Pharmaceuticals, Inc., H2 2014 150 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 151 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Kiadis Pharma B.V., H2 2014 152 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Kinex Pharmaceuticals, LLC, H2 2014 153 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Lead Discovery Center GmbH, H2 2014 154 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MaxCyte, Inc., H2 2014 155 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by medac GmbH, H2 2014 156 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MediGene AG, H2 2014 157 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MedImmune, LLC, H2 2014 158 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MEI Pharma, Inc., H2 2014 159 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Merck & Co., Inc., H2 2014 160 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Merus B.V., H2 2014 161 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 162 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Mirna Therapeutics, Inc., H2 2014 163 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Neumedicines Inc., H2 2014 164 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Novartis AG, H2 2014 166 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by NuCana BioMed Limited, H2 2014 167 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by OncoEthix SA, H2 2014 168 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by OncoImmune, Inc., H2 2014 169 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Oncothyreon Inc., H2 2014 170 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Onxeo SA, H2 2014 171 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Onyx Pharmaceuticals, Inc., H2 2014 172 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Otsuka Holdings Co., Ltd., H2 2014 173 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Oxford BioTherapeutics Ltd, H2 2014 174 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by OXiGENE, Inc., H2 2014 175 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Pfizer Inc., H2 2014 176 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Pharmedartis GmbH, H2 2014 177 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Philogen S.p.A., H2 2014 178 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Resverlogix Corp., H2 2014 179 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Rich Pharmaceuticals, Inc., H2 2014 180 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sanofi, H2 2014 181 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sareum Holdings plc, H2 2014 182 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by SBI Biotech Co., Ltd., H2 2014 183 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Seattle Genetics, Inc., H2 2014 184 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Selvita SA, H2 2014 185 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sentinel Oncology Limited, H2 2014 186 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by SpectraMab GmbH, H2 2014 187 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Stemline Therapeutics, Inc., H2 2014 188 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2014 189 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sunesis Pharmaceuticals, Inc., H2 2014 190 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Syndax Pharmaceuticals, Inc., H2 2014 191 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by SYNIMMUNE GmbH, H2 2014 192 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Synta Pharmaceuticals Corp., H2 2014 193 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Syros Pharmaceuticals, Inc., H2 2014 194 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by TetraLogic Pharmaceuticals, H2 2014 195 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 196 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Threshold Pharmaceuticals, Inc., H2 2014 197 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Tolero Pharmaceuticals, Inc., H2 2014 198 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Tragara Pharmaceuticals, Inc., H2 2014 199 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Trillium Therapeutics Inc., H2 2014 200 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Xencor, Inc., H2 2014 201 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Xenetic Biosciences plc, H2 2014 202 Assessment by Monotherapy Products, H2 2014 203 Assessment by Combination Products, H2 2014 204 Number of Products by Stage and Target, H2 2014 206 Number of Products by Stage and Mechanism of Action, H2 2014 211 Number of Products by Stage and Route of Administration, H2 2014 216 Number of Products by Stage and Molecule Type, H2 2014 218 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics - Recent Pipeline Updates, H2 2014 589 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects, H2 2014 797 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products, H2 2014 803
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
